Some of us with Birdshot are currently using adalimumab (Humira®). Rea from BUS is one of those people. We recently came across a study looking at the safety and effectiveness of long-term use of adalimumab for people with intermediate-, pan- and posterior-uveitis. This study is currently recruiting by invitation only as you do need to have been involved in the previous related studies in order to qualify.
It is being conducted across 63 locations in the US, Europe and the UK. In the UK there are three sites: London, Bristol and Aberdeen.
This study is a Phase 3, open-label multicentre study designed to evaluate long-term safety and efficacy of adalimumab in a group of adult subjects with non-infectious intermediate, posterior, or pan-uveitis.
If any of our members are enrolled in this study, we would be grateful for feed-back on this.